Client-Pharma Ltd - Accounts to registrar (filleted) - small 18.2

Client-Pharma Ltd - Accounts to registrar (filleted) - small 18.2


IRIS Accounts Production v22.2.0.402 08723939 Board of Directors Board of Directors 1.1.22 31.12.22 31.12.22 false true false false false true false Ordinary 1.00000 Ordinary B shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure087239392021-12-31087239392022-12-31087239392022-01-012022-12-31087239392020-12-31087239392021-01-012021-12-31087239392021-12-3108723939ns16:EnglandWales2022-01-012022-12-3108723939ns15:PoundSterling2022-01-012022-12-3108723939ns11:Director12022-01-012022-12-3108723939ns11:Director22022-01-012022-12-3108723939ns11:PrivateLimitedCompanyLtd2022-01-012022-12-3108723939ns11:SmallEntities2022-01-012022-12-3108723939ns11:AuditExempt-NoAccountantsReport2022-01-012022-12-3108723939ns11:SmallCompaniesRegimeForDirectorsReport2022-01-012022-12-3108723939ns11:SmallCompaniesRegimeForAccounts2022-01-012022-12-3108723939ns11:FullAccounts2022-01-012022-12-310872393912022-01-012022-12-3108723939ns11:OrdinaryShareClass12022-01-012022-12-3108723939ns11:OrdinaryShareClass22022-01-012022-12-3108723939ns11:Director32022-01-012022-12-3108723939ns11:Director42022-01-012022-12-3108723939ns11:RegisteredOffice2022-01-012022-12-3108723939ns6:CurrentFinancialInstruments2022-12-3108723939ns6:CurrentFinancialInstruments2021-12-3108723939ns6:Non-currentFinancialInstruments2022-12-3108723939ns6:Non-currentFinancialInstruments2021-12-3108723939ns6:ShareCapital2022-12-3108723939ns6:ShareCapital2021-12-3108723939ns6:RetainedEarningsAccumulatedLosses2022-12-3108723939ns6:RetainedEarningsAccumulatedLosses2021-12-3108723939ns6:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3108723939ns6:ComputerSoftware2022-01-012022-12-3108723939ns6:FurnitureFittings2022-01-012022-12-3108723939ns6:ComputerEquipment2022-01-012022-12-3108723939ns6:IntangibleAssetsOtherThanGoodwill2021-12-3108723939ns6:IntangibleAssetsOtherThanGoodwill2022-12-3108723939ns6:IntangibleAssetsOtherThanGoodwill2021-12-3108723939ns6:FurnitureFittings2021-12-3108723939ns6:ComputerEquipment2021-12-3108723939ns6:FurnitureFittings2022-12-3108723939ns6:ComputerEquipment2022-12-3108723939ns6:FurnitureFittings2021-12-3108723939ns6:ComputerEquipment2021-12-3108723939ns6:CostValuation2021-12-3108723939ns6:AdditionsToInvestments2022-12-3108723939ns6:CostValuation2022-12-3108723939ns6:WithinOneYearns6:CurrentFinancialInstruments2022-12-3108723939ns6:WithinOneYearns6:CurrentFinancialInstruments2021-12-3108723939ns6:Secured2022-12-3108723939ns6:Secured2021-12-3108723939ns6:DeferredTaxation2021-12-3108723939ns6:DeferredTaxation2022-01-012022-12-3108723939ns6:DeferredTaxation2022-12-3108723939ns11:OrdinaryShareClass12022-12-3108723939ns11:OrdinaryShareClass22022-12-31
REGISTERED NUMBER: 08723939 (England and Wales)

















Unaudited Financial Statements

For The Year Ended 31 December 2022

for

Client-Pharma Ltd

Client-Pharma Ltd (Registered number: 08723939)

Contents of the Financial Statements
For The Year Ended 31 December 2022










Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Client-Pharma Ltd

Company Information
For The Year Ended 31 December 2022







DIRECTORS: Mr G Campbell
Mr J Kilham
Mr A J S Walton-Green
Mr C Wood





REGISTERED OFFICE: Laurus House
First Avenue
Centrum 100
Burton On Trent
Staffordshire
DE14 2WH





REGISTERED NUMBER: 08723939 (England and Wales)





ACCOUNTANTS: Giess Wallis Crisp LLP
10-12 Mulberry Green
Old Harlow
Essex
CM17 0ET

Client-Pharma Ltd (Registered number: 08723939)

Statement of Financial Position
31 December 2022

2022 2021
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 14,167 24,167
Tangible assets 5 7,190 12,900
Investments 6 162 78
21,519 37,145

CURRENT ASSETS
Debtors 7 1,273,301 2,543,817
Cash at bank 1,019,996 1,601,678
2,293,297 4,145,495
CREDITORS
Amounts falling due within one year 8 778,280 2,530,664
NET CURRENT ASSETS 1,515,017 1,614,831
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,536,536

1,651,976

CREDITORS
Amounts falling due after more than one
year

9

(367,740

)

(899,271

)

PROVISIONS FOR LIABILITIES 11 (1,366 ) (2,451 )
NET ASSETS 1,167,430 750,254

CAPITAL AND RESERVES
Called up share capital 12 1,100 1,100
Retained earnings 1,166,330 749,154
SHAREHOLDERS' FUNDS 1,167,430 750,254

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Client-Pharma Ltd (Registered number: 08723939)

Statement of Financial Position - continued
31 December 2022


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22 February 2023 and were signed on its behalf by:




Mr J Kilham - Director



Mr G Campbell - Director


Client-Pharma Ltd (Registered number: 08723939)

Notes to the Financial Statements
For The Year Ended 31 December 2022


1. STATUTORY INFORMATION

Client-Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

There are no estimates and assumptions which have had a significant risk of causing a material adjustment to the carrying amount of assets and liabilities

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Computer software is being amortised evenly over its estimated useful life of three years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures & equipment - 25% on reducing balance and Straight line over 2 years
Computer equipment - Straight line over 3 years and Straight line over 2 years

Government grants
Grants relating to revenue are recognised as income on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate. Government grants have been presented as other operating income in the Income Statement.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Client-Pharma Ltd (Registered number: 08723939)

Notes to the Financial Statements - continued
For The Year Ended 31 December 2022


2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11:'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues ' of FRS 102 to all of its financial instruments

The company only enters into basic financial instruments that result in the recognition of financial assets and liabilities such as trade debtors and creditors.

Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors
Short terms debtors are measured at transaction price, less any impairment.

Cash and cash equivalents
Cash is represented by current accounts, cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Creditors
Short term creditors are measured at the transaction price.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 14 (2021 - 14 ) .

Client-Pharma Ltd (Registered number: 08723939)

Notes to the Financial Statements - continued
For The Year Ended 31 December 2022


4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 January 2022
and 31 December 2022 30,000
AMORTISATION
At 1 January 2022 5,833
Charge for year 10,000
At 31 December 2022 15,833
NET BOOK VALUE
At 31 December 2022 14,167
At 31 December 2021 24,167

5. TANGIBLE FIXED ASSETS
Fixtures Computer
& equipment equipment Totals
£    £    £   
COST
At 1 January 2022 4,367 29,209 33,576
Additions - 7,260 7,260
At 31 December 2022 4,367 36,469 40,836
DEPRECIATION
At 1 January 2022 2,873 17,803 20,676
Charge for year 1,494 11,476 12,970
At 31 December 2022 4,367 29,279 33,646
NET BOOK VALUE
At 31 December 2022 - 7,190 7,190
At 31 December 2021 1,494 11,406 12,900

6. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2022 78
Additions 84
At 31 December 2022 162
NET BOOK VALUE
At 31 December 2022 162
At 31 December 2021 78

Client-Pharma Ltd (Registered number: 08723939)

Notes to the Financial Statements - continued
For The Year Ended 31 December 2022


7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2022 2021
£    £   
Trade debtors 600,434 1,410,926
Other debtors 672,867 1,132,891
1,273,301 2,543,817

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2022 2021
£    £   
Bank loans and overdrafts 290,507 262,813
Trade creditors 95,424 345,327
Taxation and social security 120,690 34,279
Other creditors 271,659 1,888,245
778,280 2,530,664

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2022 2021
£    £   
Bank loans 367,740 899,271

10. SECURED DEBTS

The following secured debts are included within creditors:

2022 2021
£    £   
Bank loans 658,247 1,162,084

The HSBC CBILS loan is secured with a Fixed and Floating charge on all assets of the company, plus a personal guarantee from the Directors Mr J Kilham and Mr G Campbell limited to £50,000.

The IWOCA CBILS loan is personally guaranteed by the Director Mr J Kilham.

11. PROVISIONS FOR LIABILITIES
2022 2021
£    £   
Deferred tax 1,366 2,451

Deferred
tax
£   
Balance at 1 January 2022 2,451
Credit to Statement of Income and Retained Earnings during year (1,085 )
Balance at 31 December 2022 1,366

Client-Pharma Ltd (Registered number: 08723939)

Notes to the Financial Statements - continued
For The Year Ended 31 December 2022


12. CALLED UP SHARE CAPITAL



Allotted, issued and fully paid:
Number: Class: Nominal 2022 2021
value: £    £   
1,000 Ordinary £1 1,000 1,000
100 Ordinary B shares £1 100 100
1,100 1,100